| Jul 25 |
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
|
| Jul 18 |
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
|
| Jul 16 |
Blueprint Medicines: Overdue For A Breather
|
| Jun 25 |
How IBD Stock Of The Day Blueprint Medicines 'Knocked It Out Of The Park'
|
| Jun 8 |
Insider Sale: Chief Scientific Officer Percy Carter Sells Shares of Blueprint Medicines Corp (BPMC)
|
| Jun 6 |
Insider Sale at Blueprint Medicines Corp (BPMC): Chief Medical Officer L. Hewes Sells Shares
|
| May 30 |
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
|
| May 23 |
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
|
| May 21 |
Blueprint Medicines (NASDAQ:BPMC) pulls back 3.5% this week, but still delivers shareholders notable 85% return over 1 year
|
